Full-Time
AI Engineer
Collate
11-50 employees
AI-driven documentation automation for life sciences
Compensation Overview
$158k - $325k/yr
San Francisco, CA, USA
In Person
 AI & Machine Learning (1) |
|---|
Get referred to Collate
See people who can refer or advise you
- Hands-on experience building and deploying machine learning or artificial intelligence systems in production.
- Strong foundation in deploying search and retrieval systems and natural language processing applications.
- Ability to bridge research and engineering by prototyping models and shipping them in user-facing products.
- Comfort working in an early-stage startup with high ambiguity and expected ownership.
- Motivation to apply artificial intelligence to life sciences while prioritizing reliability, safety, and impact.
- Optimize prompts, conduct red-teaming, and improve the robustness of large language models for life-science natural language processing applications within Collate’s products.
- Build pipelines and infrastructure to deploy artificial intelligence systems reliably, safely, and at scale.
- Collaborate with product, design, and engineering teams to translate user needs into artificial-intelligence-driven features.
- Develop evaluation frameworks to ensure models are accurate, fair, and trustworthy in real-world life-science settings.
- Experiment rapidly while balancing iteration speed with the rigor required for high-stakes applications.
- Create tools and workflows that make artificial intelligence development more efficient across the team.
Collate provides an AI-powered platform that automates the creation and management of documentation for drug development, medical devices, and diagnostics. It works by generating, organizing, and governing regulatory and quality documents while offering data discovery and governance tools to ensure high-quality data assets. It distinguishes itself by offering an end-to-end, life-sciences–focused solution that covers drug, device, and diagnostic workflows in one platform, reducing manual work and speeding up approvals. Its goal is to shorten development and regulatory timelines so researchers can focus on discovery and bring life-saving innovations to patients faster.
Company Size
11-50
Company Stage
Series B
Total Funding
$125M
Headquarters
San Francisco, California
Founded
2025
Get referred to Collate
See people who can refer or advise you
Simplify's Take
What believers are saying
- Collate raised $95 million in June 2026 at nearly $1 billion valuation.
- Management says 50% to 90% document time savings drives urgent budget approval.
- AI paperwork demand is surging; Sarna expects most life-sciences companies to buy within nine months.
What critics are saying
- Veeva’s June 2026 Vault AI and Falcon directly attack Collate’s core documentation workflow.
- Life-sciences buyers already trust Veeva’s entrenched system, compressing Collate’s sales cycles in 2026.
- If major pharmaceutical customers standardize on Veeva, Collate becomes a feature, not a company.
What makes Collate unique
- Surbhi Sarna’s 2018 Boston Scientific exit and YC pedigree build instant life-sciences credibility.
- Collate targets GxP documentation with human-in-loop audits, matching regulated workflow requirements.
- The platform won 50 customers since May 2025, including pharma, device, and biotech firms.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 21%1 year growth
↑ 21%2 year growth
↓ -2%Surbhi Sarna, CEO and founder of Collate, discussed her company's AI-native software that automates documentation for life-sciences companies bringing drugs and devices to market. The GxP-compliant platform maintains human oversight for audits. Sarna's journey into healthcare technology began as a teenager when she was hospitalised with debilitating ovarian cysts, facing uncertainty about whether she had cancer. This experience motivated her to found nVision Medical, which was later acquired by Boston Scientific. Collate addresses the extensive documentation requirements in the pharmaceutical and medical device industries, streamlining regulatory compliance processes whilst ensuring proper human verification remains in place.
AI startup Collate has raised $95 million in a Series C round led by Redpoint Ventures, valuing the company at nearly $1 billion. The funding brings total capital raised to $125 million since the San Francisco-based company emerged from stealth 17 months ago. Founded by two-time entrepreneur and former Y Combinator partner Surbhi Sarna, Collate automates paperwork for life sciences companies, including regulatory filings and clinical trial documentation. The startup has signed approximately 50 customers since May 2025, including major pharmaceutical companies and medical device manufacturers. Collate's AI tools deliver time savings of 50% to 90% on documents that previously took months to complete, whilst maintaining accuracy above 90%. The company requires human verification before documents are exported to ensure patient safety.
Biotech startup Collate, founded by Surbhi Sarna, has secured a $30 million seed fund to automate paperwork in the life sciences industry using AI. The funding round was led by Redpoint, with participation from First Round, Conviction Partners, and YC, valuing Collate at over $100 million. Collate aims to streamline documentation for diagnostic, medical device, and drug development companies, enhancing R&D and reducing time to market. Co-founders Nate Smith and Jigish Patel bring additional expertise.
Y Combinator's Surbhi Sarna has raised $30 million for Collate, a startup aiming to automate the tedious parts of running a life sciences business using AI.